Moderne Therapie der primär biliären Cholangitis-Reference-Cited by-同舟云学术

Moderne Therapie der primär biliären Cholangitis

Published:2017-11-06 Issue:1 Volume:59 Page:105-112
ISSN:0020-9554
Container-title:Der Internist
language:de
Short-container-title:Internist

Author:

Strassburg C. P.

Publisher

Springer Science and Business Media LLC

Subject

Internal Medicine

Link

http://link.springer.com/article/10.1007/s00108-017-0347-4/fulltext.html

Reference32 articles.

1. Angulo P, Jorgensen RA, Keach JC et al (2000) Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 31:318–323

2. Beuers U, Gershwin ME, Gish RG et al (2015) Changing nomenclature for PBC: from ‚cirrhosis‘ to ‚cholangitis‘. J Hepatol 63(5):1285–1287. https://doi.org/10.1016/j.jhep.2015.06.031

3. Bundesärztekammer (2017) Richtlinien zur Transplantationsmedizin. http://www.bundesaerztekammer.de/richtlinien/richtlinien/transplantationsmedizin . Zugegriffen: 27.09.2017

4. Carbone M, Mells G, Pells G et al (2012) Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology 144(3):560–569.e7. https://doi.org/10.1053/j.gastro.2012.12.005

5. Corpechot C, Chazouilleres O, Poupon R (2011) Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol 55:1361–1367

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of LH10, a novel fexaramine-based FXR agonist for the treatment of liver disease;Bioorganic Chemistry;2024-02

2. Neue Arzneimittel 2017;Arzneiverordnungs-Report 2018;2018